The U.S. Food and Drug Administration (FDA) announced Wednesday that the nationwide shortage of 0.9 percent sodium chloride intravenous (IV) saline has officially ended.
FDA Commissioner Dr. Marty Makary credited the resolution to a coordinated effort between the FDA, the Administration for Strategic Preparedness and Response, and industry partners.
The agencies worked together to boost manufacturing, stabilize supply chains, and maintain access by allowing temporary IV solution imports, expediting manufacturing reviews, and extending product expiration dates.
With the shortage resolved, the sodium chloride 0.9 percent injection will be removed from the FDA Drug Shortage Database. Healthcare facilities are encouraged to continue using FDA-approved products as they become available.
Dr. Makary emphasized that the FDA will maintain vigilance over medical supply levels. “The FDA remains focused on doing all we can to help mitigate shortages and prevent them from occurring,” he said. “We will continue working diligently to monitor supply levels, anticipate potential disruptions, and support a robust, secure, and transparent supply chain for medical products.”
The agency also noted that efforts are ongoing with manufacturers to address shortages of other IV fluids and ensure consistent access to critical medical products nationwide.
READ MORE
Medicare Part D Premiums Could Climb by $50 Monthly in 2025
Maine Clinics Fight Medicaid Cuts in Court Over Abortion Rule
KRAS-Targeting Vaccine May Prevent Recurrence of Lethal Pancreatic Cancer
